590 related articles for article (PubMed ID: 19761423)
21. Updated clinical information on multitargeted antifolates in lung cancer.
Scagliotti GV; Ceppi P; Capelletto E; Novello S
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S35-40. PubMed ID: 19362945
[TBL] [Abstract][Full Text] [Related]
22. Overview of MTA in the treatment of non-small cell lung cancer.
Postmus PE; Green MR
Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519
[TBL] [Abstract][Full Text] [Related]
23. Pemetrexed in advanced non-small cell lung cancer.
Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
[TBL] [Abstract][Full Text] [Related]
24. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
26. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
Xu B; Liu P; Yin Y; Liu P; Shu Y
Biomed Pharmacother; 2013 Oct; 67(8):763-9. PubMed ID: 23790249
[TBL] [Abstract][Full Text] [Related]
28. The place of pemetrexed in the management of non-small-cell lung cancer patients.
Tomasini P; Greillier L; Khobta N; Barlesi F
Expert Rev Anticancer Ther; 2013 Mar; 13(3):257-66. PubMed ID: 23477511
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
30. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
32. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
33. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
[TBL] [Abstract][Full Text] [Related]
34. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Ferraldeschi R; Thatcher N; Lorigan P
Expert Rev Anticancer Ther; 2007 May; 7(5):635-40. PubMed ID: 17492928
[TBL] [Abstract][Full Text] [Related]
35. New developments in chemotherapy for advanced non-small cell lung cancer.
Raez LE; Lilenbaum R
Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
[TBL] [Abstract][Full Text] [Related]
36. [Pemetrexed salvage chemotherapy for NSCLC: implementation study].
Jungels C; Berghmans T; Meert AP; Lafitte JJ; Scherpereel A; Sculier JP
Rev Mal Respir; 2012 Jan; 29(1):21-7. PubMed ID: 22240216
[TBL] [Abstract][Full Text] [Related]
37. Review of a promising new agent--pemetrexed disodium.
Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
[TBL] [Abstract][Full Text] [Related]
38. [Pemetrexed development in oncology].
Chaigneau L; Villanueva C; Thierry-Vuillemin A; Legat-Fagnoni C; N'Guyen T; Maurina T; Lorgis V; Pivot X
Bull Cancer; 2007; 94 Spec No Actualites():S142-8. PubMed ID: 17845985
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy for advanced stage non-small cell lung cancer.
Fathi AT; Brahmer JR
Semin Thorac Cardiovasc Surg; 2008; 20(3):210-6. PubMed ID: 19038730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
